title: Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls.
abstract: BACKGROUND
  M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced nonsmall- cell lung cancer (NSCLC) compared with those in a healthy group.
  
  
  METHODS
  Thirty-two patients with advanced NSCLC and thirty-two healthy people were included in the study. Serum M30 and M65 values were measured by quantitative ELISA method. The best cut-off value for serum M65 was calculated by ROC analysis and then univariate analysis was performed to determine the importance of M65 value in predicting progression-free survival (PFS).
  
  
  RESULTS
  There were no differences between mean serum M30 values between patients and controls (445.44±536.17 vs. 340.56±345.07, p=1). The mean serum M65 values were found to be significantly higher in patients than in healthy controls (1421.30±1662.59 vs. 648.85±341.17, p<0.001). The best cut-off value for serum M65 predicting PFS was 1311.64 U/l (AUC 0.58, sensitivity and specificity were 45.5% and 85.7% respectively). The patients with serum M65 values ≥1311.64 U/l had worse PFS than patients with serum M65 values <1311.64 U/l, p=0.01). There was no correlation between serum M30 value and PFS in the patient group (p=0.4).
  
  
  CONCLUSIONS
  Our results indicated that serum M65 values elevated in advanced NSCLC compared to a healthy control group and elevated serum M65 level can predict PFS in patients.
authors.affiliation: Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey. basakoven@yahoo.com
authors.forename: Basak
authors.initials: B
authors.lastname: Oven Ustaalioglu
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.forename: Serif
authors.initials: S
authors.lastname: Ercan
authors.forename: Asuman
authors.initials: A
authors.lastname: Orcun
authors.forename: Mesut
authors.initials: M
authors.lastname: Seker
authors.forename: Alper
authors.initials: A
authors.lastname: Ozkan
authors.forename: Recep
authors.initials: R
authors.lastname: Ustaalioglu
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053538:Keratin-18 / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D053538:Keratin-18